Ipamorelinsafety profile & UK regulatory status

This page summarises the published safety profile, contraindications, formulation interactions, and UK regulatory status for Ipamorelin as reported in the pre-clinical research literature. It is a research-orientation reference and not a clinical safety assessment. Ipamorelin is not licensed as a medicine in the United Kingdom and may not be supplied or administered to humans outside an authorised clinical-trial framework.

Safety profile

Acute safety data for ipamorelin in healthy human subjects come primarily from the Raun 1998 characterisation and subsequent Phase I work. Single subcutaneous and intravenous doses across the research dose range produced mild, transient adverse events: brief flushing and warmth following IV bolus, occasional mild transient headache, and infrequent nausea at higher doses. No clinically significant changes in heart rate, blood pressure, or routine haematology/biochemistry were observed at therapeutic dose ranges. No serious adverse events attributable to ipamorelin itself have been documented in the published trials. The defining safety feature is the absence of cortisol/ACTH and prolactin elevation seen with other GHRP-class compounds. GHRP-6 produces 2- to 4-fold cortisol spikes and modest prolactin elevation; GHRP-2 has reduced but non-zero cortisol effects; ipamorelin produces no measurable elevation in either at the GH-stimulating dose range. This selectivity is the principal pharmacological argument for ipamorelin over alternative GHRPs in research where GH-axis isolation is the experimental goal — co-stimulation of cortisol would confound metabolic and immune endpoints in unwanted ways. Chronic-dosing safety data for ipamorelin in humans are limited; Phase II development did not progress, and most chronic-dosing experience derives from research-chemical-community use rather than published clinical trials. Theoretical concerns parallel those for other GH-axis peptides: chronic supraphysiological IGF-1 elevation theoretically carries oncogenic risk through IGF-1R activation; insulin resistance is a documented complication of sustained GH/IGF-1 elevation; the pulsatile-pattern preservation of ipamorelin protocols is expected to mitigate but not eliminate this risk. Ipamorelin's pentapeptide structure (711 Da) is at the lower end of immunogenicity risk; the use of D-amino acids and N-terminal Aib substitution further reduces antibody-response likelihood. Anti-drug antibodies have not been a reported issue in published data. Sterility and endotoxin content of research-chemical-grade preparations remain the dominant practical safety variables, as with all injectable research peptides. No acute hypotension, anaphylaxis, or serious immediate adverse events have been documented at research-protocol doses. The acute safety record is favourable; the chronic-dosing record is necessarily limited by the absence of completed Phase II/III programmes.

UK regulatory status

Ipamorelin is not authorised as a medicinal product by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and holds no marketing authorisation in any jurisdiction. It is not a controlled substance under the Misuse of Drugs Act 1971. Ipamorelin is captured by the World Anti-Doping Agency (WADA) Prohibited List under category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) as a growth-hormone secretagogue. Athletes subject to anti-doping testing should treat ipamorelin and all GHRP-class peptides as prohibited both in-competition and out-of-competition regardless of claimed research purpose. The compound is captured by IGF-1 elevation monitoring and by GH-isoform-ratio testing in addition to direct peptide identification. MHRA enforcement actions concerning ipamorelin supply specifically have not been published in the public domain. Generic MHRA warnings on unlicensed peptide supply for human use apply. Research-grade ipamorelin for in-vitro and animal research is available from research-chemical suppliers; possession for bona fide laboratory research is generally unrestricted in the UK. Supply or administration to humans outside an authorised clinical-trial framework engages the Human Medicines Regulations 2012 and is generally an offence. For animal research under ASPA (Animals (Scientific Procedures) Act 1986), ipamorelin work in vertebrates requires Personal, Project, and Establishment Licences from the Home Office Drugs and Firearms Licensing Unit, and the work must pass a local Animal Welfare and Ethical Review Body assessment.

What 'research-use-only' means in the UK

The UK regulatory position on research peptides sits across four distinct frameworks: MHRA medicines licensing, the Human Medicines Regulations 2012, the Misuse of Drugs Act 1971, and the WADA Prohibited List. Ipamorelin is not an MHRA-licensed medicine; possession for bona fide in-vitro or ex-vivo laboratory research is generally lawful, while supply or administration to humans engages the Human Medicines Regulations and is generally an offence. For animal-research use, additional permissions are required under the Animals (Scientific Procedures) Act 1986 (ASPA).

For the comprehensive UK regulatory reference covering all four frameworks, see the UK research peptide regulation 2026 reference.

Practical safety considerations for research

Sterility and endotoxin content of research-grade preparations remain the dominant practical safety variables for any injectable in-vivo work, regardless of the intrinsic safety profile of the active peptide. Batch-to-batch verification of HPLC purity and identity (by mass spectrometry where possible) and endotoxin testing by limulus amebocyte lysate (LAL) assay or recombinant Factor C (rFC) assay are standard due-diligence expectations. For research with vertebrate animals in the UK, ASPA project and personal licences are mandatory and the work must pass a local Animal Welfare and Ethical Review Body assessment.

For full Ipamorelin research context including mechanism, study citations, and references, see the main Ipamorelin research profile. For dosing and pharmacokinetic context, see the dosing reference and half-life reference pages.